Curated for Orthogate.org Members

EXECUTIVE SUMMARY

• Avalanche Medical Awarded FDA Breakthrough Device Designation for SyCap Focal Knee Resurfacing Implant: MedTech biomaterials innovator Avalanche Medical received FDA Breakthrough Device Designation for SyCap, a non-degradable polymer resurfacing implant designed to treat focal knee osteochondral defects without joint sacrifice.
• Spineart & eCential Robotics Secure FDA 510(k) Clearance for PERLA® TL Robotic Application: Spineart and eCential Robotics obtained FDA 510(k) clearance for the PERLA® TL planning and navigation app, enabling robotic-assisted pedicle screw placement and instrumentation on the eCential open robotic platform.
• GMReis Obtains FDA Clearance for High-Strength STITCH Suture Platform: GMReis secured FDA 510(k) clearance for its STITCH surgical suture portfolio, delivering high-tensile UHMWPE constructs for sports medicine, rotator cuff, and soft-tissue reconstruction.

DAILY ANNOUNCEMENTS BY CATEGORY

Joint Preservation & Biomaterials

Avalanche Medical — Receives FDA Breakthrough Device Designation for SyCap Focal Knee Resurfacing Implant

• Summary: Avalanche Medical announced that the U.S. FDA has granted Breakthrough Device Designation for its SyCap knee resurfacing implant. Composed of a proprietary non-degradable synthetic polymer, SyCap is engineered to replace damaged focal articular cartilage and subchondral bone defects in the femoral condyle, providing immediate structural load-bearing capacity and a low-friction articulating surface against native tibial cartilage. The technology serves as a vital bridge between biologic cartilage repair and total/unicompartmental knee arthroplasty.
• Key Details:
  • Device/System Name: SyCap Non-Degradable Polymer Focal Knee Resurfacing Implant
  • Status: FDA Breakthrough Device Designation Granted
  • Clinical Significance: Offers an off-the-shelf, motion-preserving synthetic solution for severe focal chondral defects, relieving joint pain while delaying the need for partial or total knee replacement in active patients.
• Original Source: Avalanche Medical Breakthrough Device Release — ORTHOWORLD

Surgical Robotics, AI & Navigation

Spineart & eCential Robotics — FDA 510(k) Clearance for PERLA® TL Application on eCential Op'n Platform

• Summary: Spineart and eCential Robotics announced FDA 510(k) clearance for the PERLA® TL navigation and robotic software application. The software enables seamless preoperative planning and intraoperative execution of Spineart's PERLA® thoracolumbar pedicle screw system directly on eCential's open robotic navigation platform. The integrated workflow combines low-dose 2D/3D intraoperative imaging, real-time optical tracking, and robotic arm trajectory guidance.
• Key Details:
  • Device/System Name: PERLA® TL Software & eCential Op'n Robotic Navigation Platform
  • Status: FDA 510(k) Cleared
  • Clinical Significance: Enhances pedicle screw placement trajectory accuracy, reduces operative duration and intraoperative radiation exposure, and expands robotic versatility in complex thoracolumbar spine procedures.
• Original Source: Spineart & eCential FDA Clearance — OrthoSpineNews

Sports Medicine & Soft Tissue Reconstruction

GMReis — Receives FDA 510(k) Clearance for STITCH Non-Absorbable High-Strength Surgical Sutures

• Summary: GMReis secured FDA 510(k) clearance for its STITCH surgical suture portfolio in the United States. Manufactured from medical-grade ultra-high-molecular-weight polyethylene (UHMWPE), the suture line includes high-strength braided sutures and tubular sleeves designed for soft-tissue reattachment, sports medicine repairs, and integration with all-suture anchors and flexible orthopaedic fixation constructs.
• Key Details:
  • Device/System Name: STITCH Non-Absorbable Surgical Suture System
  • Status: FDA 510(k) Cleared / US Commercial Expansion
  • Clinical Significance: Delivers high tensile strength, knot security, and abrasion resistance for rotator cuff, glenoid labrum, and ligamentous soft-tissue reconstructions.
• Original Source: GMReis FDA Clearance Announcement — ORTHOWORLD

Clinical Evidence & Perioperative Medicine

Orthopedics This Week — GLP-1 Receptor Agonists and 90-Day Arthroplasty Outcomes

• Summary: Clinical research featured in Orthopedics This Week analyzed 90-day postoperative outcomes among diabetic and obese patients undergoing primary total hip and total knee arthroplasty while receiving GLP-1 receptor agonist therapy. While sustained weight reduction and metabolic control provide long-term joint health benefits, the investigation identified critical perioperative considerations regarding delayed gastric emptying during anesthesia induction, recommending clear multi-specialty withholding protocols prior to elective joint replacement.
• Key Details:
  • Device/System Name: Perioperative GLP-1 Clinical Protocol Guidelines
  • Status: Clinical Evidence Review
  • Clinical Significance: Informs preoperative patient optimization, minimizing pulmonary aspiration risks and gastrointestinal complications during elective arthroplasty.
• Original Source: GLP-1 Arthroplasty Clinical Review — Orthopedics This Week

NEW FDA 510(k) & PMA CLEARANCE LISTING (PAST 24–48 HOURS)